Skip to main content

Table 3 Treatment patterns assessed during the 12-month follow-up using IPT-weighted cohorts

From: Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia

 

IPT-weighted recently diagnosed cohort

IPT-weighted overall cohort

PP1M

OAA

P-valuea

PP1M

OAA

P-valuea

(N = 1107)

(N = 1288)

(N = 11,612)

(N = 12,688)

Duration of continuous exposure to index agent (days)b, mean ± SD [median]

217.7 ± 128.4 [225.0]

189.4 ± 123.2 [152.0]

0.0017*

215.8 ± 128.8 [193.0]

194.4 ± 123.1 [160.0]

<.0001*

Number of dispensings of index agent, mean ± SD [median]

7.7 ± 4.4 [8.0]

7.9 ± 6.4 [6.0]

0.4888

7.8 ± 4.4 [7.0]

8.0 ± 5.8 [7.0]

0.1489

Adherence (PDC ≥ 80%) on index agent, %

28.8%

21.1%

<.0001*

26.7%

22.7%

<.0001*

 PDC on index agent, mean ± SD [median]

0.53 ± 0.30 [0.55]

0.47 ± 0.30 [0.41]

0.0062*

0.53 ± 0.30 [0.52]

0.49 ± 0.30 [0.44]

<.0001*

Adherence (PDC ≥ 80%) on any AP agent, %

43.2%

40.2%

0.1420

39.3%

38.4%

0.1534

 PDC on any AP agent, mean ± SD [median]

0.65 ± 0.28 [0.71]

0.64 ± 0.29 [0.70]

0.7028

0.63 ± 0.29 [0.69]

0.64 ± 0.28 [0.67]

0.3509

Persistence on index agent, %

 No gap ≥30 days

21.8%

18.0%

0.0203*

21.9%

19.1%

<.0001*

 No gap ≥60 days

38.7%

27.6%

<.0001*

37.8%

29.0%

<.0001*

 No gap ≥90 days

46.9%

35.1%

<.0001*

43.8%

36.1%

<.0001*

Persistence on any AP agent, %

 No gap ≥30 days

31.2%

35.0%

0.0548

32.9%

33.0%

0.8544

 No gap ≥60 days

53.2%

50.3%

0.1518

48.9%

47.1%

0.0046*

 No gap ≥90 days

64.8%

59.9%

0.0132*

56.5%

56.0%

0.3737

Psychiatric medication use during follow-up (excluding index agent), %

73.4%

93.5%

<.0001*

82.1%

94.8%

<.0001*

 AP use

56.3%

67.9%

<.0001*

59.1%

64.8%

<.0001*

  Typical oral and short-term injectable

21.7%

26.1%

0.0128*

22.3%

24.9%

<.0001*

  Atypical oral and short-term injectable

52.9%

52.6%

0.8815

49.5%

48.4%

0.0892

  Typical LAI

3.0%

5.9%

0.0010*

4.6%

6.9%

<.0001*

  Atypical LAI

4.6%

14.0%

<.0001*

2.9%

11.5%

<.0001*

 Other psychiatric medication use

69.0%

87.2%

<.0001*

75.2%

89.5%

<.0001*

  Anxiolytics

31.9%

50.7%

<.0001*

47.6%

58.4%

<.0001*

  Mood stabilizers

40.0%

56.4%

<.0001*

40.6%

52.5%

<.0001*

  Antidepressants

49.6%

66.8%

<.0001*

54.5%

70.1%

<.0001*

AP polypharmacy presentc, %

16.6%

26.3%

<.0001*

23.6%

29.2%

<.0001*

Psychiatric polypharmacy presentd, %

45.2%

62.4%

<.0001*

49.7%

67.7%

<.0001*

  1. AP antipsychotics, IPT inverse probability of treatment, LAI long-acting injectable therapy, OAA oral atypical antipsychotics, PDC proportion of days covered, PP1M once-monthly paliperidone palmitate
  2. aCalculated using the Pearson chi-square test (categorical variables) and Student’s t-test (continuous variables)
  3. bContinuous exposure with the agent (PP1M or specific OAA) that was used to define the index date. Continuous therapy was defined as having a gap of no more than 90 days between two claims for the index agent
  4. cAP polypharmacy is defined as having overlapping coverage of ≥2 unique AP agents for at least 60 consecutive days with no gaps larger than 7 days.
  5. dPsychiatric polypharmacy is defined as having overlapping coverage of ≥1 AP agent and ≥1 anxiolytic, antidepressant, or mood stabilizer for at least 60 consecutive days with no gaps larger than 7 days
  6. *indicates that p-value <0.05
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us